Medications

Mivavotinib for relapsed/refractory B-cell lymphoma

In a new research paper published in Oncotarget, researchers report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib. They present data for ...

page 1 from 21